Answers are grounded in this paper and cite their sources.
Chronic pain and emotional disorders, particularly depression and anxiety, are highly comorbid and mutually reinforcing, but their shared mechanisms remain unclear. This review highlights the hypothalamic paraventricular nucleus (PVN) as a key hub integrating stress, pain, and emotion, with a focus on two opposing neuropeptide systems: corticotropin-releasing hormone (CRH) and oxytocin (OXT). Chronic pain and stress promote sustained CRH activation and hypothalamic-pituitary-adrenal (HPA) axis dysregulation, thereby favoring pain sensitization and negative affect, whereas OXT exerts analgesic, anxiolytic, and antidepressant effects. We propose that CRH-driven HPA hyperactivity coupled with relative OXT insufficiency is the core mechanism underlying pain-emotion comorbidity, further amplified by neuroinflammation and immune-neural crosstalk. We also summarize current pharmacological and non-pharmacological interventions targeting this circuitry and discuss emerging directions, including single-cell and spatial transcriptomics, circuit-specific manipulations, brain-penetrant ligands, and stratified neuromodulation. The PVN-centered framework may facilitate the development of precise therapies for patients with chronic pain and emotional disorders.
No takes yet. Share an insight, caveat, or question.
Su et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: